first
report
coronaviru
diseas
caus
novel
sever
acut
respiratori
syndrom
coronaviru
scientif
commun
work
field
type
iii
ifn
realiz
class
ifn
could
play
import
role
emerg
viral
infect
viewpoint
present
opinion
benefit
potenti
limit
use
prevent
limit
treat
danger
viral
infect
infect
emerg
major
global
threat
first
report
china
end
outbreak
rapidli
spread
throughout
globe
declar
pandem
world
health
organ
march
absenc
approv
therapi
vaccin
prevent
treat
infect
rapid
dissemin
overwhelm
public
healthcar
system
worldwid
caus
sever
econom
social
distress
previou
high
mortal
outbreak
caus
middl
east
respiratori
syndrom
mer
cov
illustr
emerg
novel
virus
isol
occurr
howev
former
outbreak
differ
substant
transmit
asymptomat
individu
current
primari
tool
mitig
social
distanc
effect
antivir
pharmacolog
agent
would
import
clinic
public
health
tool
wide
spectrum
virus
directli
caus
human
diseas
rang
sever
asymptomat
life
threaten
host
surviv
depend
upon
key
factor
includ
cellular
mechan
innat
antivir
immun
respons
intend
counter
viru
replic
virusspecif
lymphocyt
elimin
infect
therefor
develop
therapeut
intervent
strategi
augment
intrins
earli
broadspectrum
antivir
mechan
desir
although
biolog
life
cycl
pathogenesi
differ
virus
wide
diverg
ifn
activ
protect
mechan
aim
viru
control
elimin
administr
ifn
use
prophylaxi
well
earli
therapi
predic
principl
supplement
compens
insuffici
ifn
product
activ
might
activ
block
viru
decad
type
ifn
explor
mediat
rapid
innat
antivir
protect
novel
group
three
cytokin
known
type
iii
ifn
discov
act
independ
type
ifn
establish
antivir
resist
cell
kotenko
et
al
sheppard
et
al
addit
member
famili
discov
prokuninaolsson
et
al
inform
function
gener
use
mous
model
thu
critic
evalu
relat
human
diseas
ye
et
al
distinct
action
type
type
iii
ifn
achiev
engag
separ
nonoverlap
heteromer
receptor
complex
ifnar
complex
subunit
type
ifn
ifnl
complex
subunit
type
iii
ifn
fig
signal
pathway
set
ifnstimul
gene
isg
induc
ifn
remark
similar
redund
crotta
et
al
galani
et
al
ifnar
express
cell
ifnlr
limit
express
restrict
epitheli
cell
subset
immun
cell
includ
neutrophil
due
specif
express
pattern
type
ifn
provid
system
respons
guard
epitheli
surfac
broggi
et
al
fig
type
ifn
use
treat
chronic
hepat
c
viru
hepat
b
viru
infect
may
potenti
protect
patient
outbreak
virus
howev
treatment
signific
system
side
effect
due
ubiquit
express
ifnar
mice
found
effect
prevent
treat
influenza
viru
infect
increas
inflamm
tissu
damag
compar
davidson
et
al
galani
et
al
also
potent
restrict
viral
dissemin
nasal
epithelium
upper
respiratori
tract
klinkhamm
et
al
clinic
trial
treatment
chronic
hepat
c
viru
infect
document
fewer
milder
side
effect
equal
efficaci
compar
therapi
muir
et
al
studi
suggest
specif
advantag
antivir
therapeut
epitheli
surfac
time
spare
new
pharmaceut
develop
race
repurpos
exist
drug
compel
case
made
therapeut
pegyl
current
avail
therapeut
agent
vitro
treatment
show
potenc
varieti
virus
includ
merscov
main
function
prevent
viral
infect
establish
antivir
state
infect
slow
viral
replic
dissemin
contrast
ifnar
ifnlr
larg
absent
rest
immun
cell
human
mice
notabl
except
neutrophil
blazek
et
al
broggi
et
al
espinosa
et
al
human
b
cell
goel
et
al
allow
avoid
minim
system
inflamm
caus
treatment
type
ifn
broggi
et
al
fig
sever
lung
inflamm
tissu
damag
hallmark
significantli
contribut
mortal
infect
mehta
et
al
thu
enhanc
inflamm
cytokin
storm
must
avoid
howev
remain
elucid
whether
ifnlr
upregul
upon
stimul
highli
inflam
environ
increas
risk
possibl
advers
effect
human
cell
espinosa
et
al
goel
et
al
absenc
proinflammatori
effect
lung
davidson
et
al
forero
et
al
galani
et
al
one
import
argument
specif
advantag
type
ifn
treatment
option
howev
import
establish
immun
cell
respons
figur
potenti
benefit
use
type
iii
ifn
prevent
treatment
type
ifn
signal
heterodimer
receptor
complex
ifnar
compris
subunit
ifnar
activ
induc
express
isg
trigger
proinflammatori
respons
via
recruit
activ
immun
cell
promot
antivir
state
host
ifnar
express
cell
administr
type
ifn
seriou
system
side
effect
contrast
type
iii
ifn
signal
distinct
receptor
complex
ifnlr
consist
subunit
express
restrict
epitheli
cell
subset
immun
cell
includ
neutrophil
therefor
type
iii
ifn
administr
prophylact
treatment
earli
stage
would
result
isg
express
antivir
respons
local
epitheli
cell
reduc
side
effect
inflamm
associ
system
action
type
ifn
activ
exacerb
inflamm
also
remain
seen
whether
share
known
antiprolif
effect
type
ifn
whether
could
imped
repair
process
recoveri
sensit
epitheli
cell
virusinduc
cell
death
addit
bacteri
superinfect
associ
sever
case
zhang
et
al
preprint
although
vari
clinic
studi
type
ifn
known
detriment
select
bacteri
infect
model
davidson
et
al
exampl
ifnlr
mice
show
improv
bacteri
control
virusbacteria
superinfect
model
planet
et
al
ectop
induct
product
prove
detriment
mice
previous
infect
influenza
rich
et
al
type
ifn
often
suppress
antibacteri
action
immun
cell
may
employ
rout
facilit
bacteri
superinfect
reduct
neutrophil
recruit
blazek
et
al
rich
et
al
andor
neutrophil
bactericid
activ
broggi
et
al
although
mous
model
fulli
recapitul
human
diseas
respect
activ
anim
studi
give
mandat
care
evalu
use
therapeut
agent
although
restrict
express
pattern
may
advantag
potenti
deleteri
proinflammatori
effect
may
come
cost
efficaci
inde
induc
antivir
program
cell
express
still
debat
whether
alveolar
macrophag
endotheli
cell
product
infect
could
serv
viru
reservoir
access
antivir
action
lack
may
better
suit
type
ifn
hostdirect
therapi
studi
need
immedi
assess
possibl
detriment
effect
factor
use
although
yet
use
activ
diseas
increas
risk
lung
infect
emerg
clinic
studi
patient
treat
wk
potenti
advers
effect
might
also
minim
shorter
durat
treatment
exampl
propos
phase
iii
clinic
trial
chronic
hepat
viru
dose
weekli
wk
preced
phase
ii
studi
clinicaltrialsgov
identifi
howev
case
acut
one
two
dose
deem
suffici
current
design
random
clinic
trial
approach
could
provid
immedi
protect
healthcar
worker
person
high
risk
infect
earli
stage
infect
patient
show
sign
inflammatori
reaction
especi
lung
mani
outstand
question
relat
need
understand
whether
viru
induc
endogen
express
andor
block
respons
age
differ
express
receptor
explain
sever
diseas
older
patient
effect
inflammatori
respons
mechan
tissu
damag
repair
activ
measur
clinic
trial
develop
also
advoc
open
access
scientif
commun
result
clinic
trial
ensur
expert
interpret
inform
measur
pandem
illustr
unmet
need
prophylact
rapidrespons
measur
boost
antivir
host
respons
ifn
specif
might
address
need
broadspectrum
antivir
biolog
could
help
pandem
outbreak
also
futur
viral
threat
